Key facts
- Longeviti’s last known valuation is $110.0M (Feb 2025).
- It has raised $38.8M; the latest was Later Stage VC ($10.0M) in Aug 2025.
- Notable investors include TEDCO, Soleus Capital, Abell Foundation, Ecphora Capital, Blueprint Medtech — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Longeviti
- ·The full record, as it builds
Funding rounds
No funding rounds for Longeviti are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Longeviti
Operaror of a neuro-technology company intended to innovate manufacturing and globally distribute functional neurosurgical implants for complex brain surgeries. The company's products provide space within the brain or skull to fit lifesaving neuro technologies, including valves, brain-computer interface, drains, intracranial pressure diagnostics, and blood brain barrier BBB drug delivery capabilities, enabling healthcare practitioners and patients to retrieve lifesaving neuro information in seconds and real-time, versus traditional imaging and diagnostic methods.
- Sector
- Healthcare
- HQ
- Hunt Valley, MD, United States
- Founded
- 2016
- Employees
- 44
- Website
- longeviti.com/
- Ownership
- Privately Held (backing)
Longeviti doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Longeviti shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Longeviti in its N-PORT filings yet. We sweep new filings monthly.